Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
Cancer Therapy: Clinical

Interaction of Molecular Markers and Physical Activity on Mortality in Patients with Colon Cancer

Jeffrey A. Meyerhardt, Shuji Ogino, Gregory J. Kirkner, Andrew T. Chan, Brian Wolpin, Kimmie Ng, Katsuhiko Nosho, Kaori Shima, Edward L. Giovannucci, Massimo Loda and Charles S. Fuchs
Jeffrey A. Meyerhardt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shuji Ogino
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory J. Kirkner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew T. Chan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian Wolpin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kimmie Ng
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katsuhiko Nosho
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kaori Shima
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward L. Giovannucci
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Massimo Loda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles S. Fuchs
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1078-0432.CCR-09-0496 Published September 2009
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Purpose: Physical activity in colon cancer survivors has been associated with lower cancer recurrences and improved survival. Whether molecular features of the tumor portend more or less likelihood for benefit from exercise is unknown.

Experimental Design: Using two large prospective cohort studies with physical activity assessments after colon cancer diagnosis, we examined expression of fatty acid synthase, p53, p21, and p27 and mutational status of K-ras and phosphatidylinositol 3-kinase(PI3KCA). We calculated hazard ratios (HR) of colon cancer–specific mortality, adjusted for tumor and patient characteristics, and tested for molecular interactions with exercise.

Results: In a cohort of 484 men and women with stage I to III colon cancer, patients who engaged in at least 18 metabolic equivalent task (MET)–hours per week after diagnosis had an adjusted HR for colon cancer–specific mortality of 0.64 [95% confidence interval (95% CI), 0.33-1.23] and for overall mortality of 0.60 (95% CI, 0.41-0.86). A statistically significant interaction was detected based on p27 expression (P = 0.03). For tumors with loss of p27 (n = 195), physical activity of ≥18 MET-hours/week led to a HR for colon cancer mortality of 1.40 (95% CI, 0.41-4.72), compared with those with <18 MET-hours/week. However, for tumors with expression of p27 (n = 251), the adjusted HR was 0.33 (95% CI, 0.12-0.85). Molecular status of fatty acid synthase, K-ras, p53, p21, and PI3KCA did not influence the association between exercise and colon cancer–specific or overall mortality.

Conclusion: The benefit of physical activity on outcomes in patients with stage I to III colon cancer may be influenced by p27 status. Further studies are warranted to confirm these findings. (Clin Cancer Res 2009;15(18):5931–6)

  • colon cancer
  • exercise
  • molecular markers

Translational Relevance

Colorectal cancer is the fourth most common cancer diagnosed in the United States. Eighty percent of patients are diagnosed with nonmetastatic disease and treated with curative intent with surgery with or without adjuvant therapy. Despite standard therapy, up to 40% of patients will recur and adjunctive therapy to standard treatment is of great interest. Recent data suggest that colon cancer survivors who are physically active have improved disease-free and overall survival after diagnosis compared with those that are relatively inactive. To further explore those observations, we tested whether physical activity is more or less beneficial toward survival in colon cancer subgroups as defined by molecular markers.

Physically active people have a reduced risk of developing colon cancer (1–11). A meta-analysis of 19 cohort studies showed a statistically significant 22% reduction in the risk of colon cancer in active males and 29% reduction in active females (12). The IARC concluded that the evidence supports a causal relation between inactivity and colon cancer risk (13). In two large prospective observational studies of colon cancer patients, physical activity after colon cancer diagnosis was associated with significant improvements in colon cancer recurrences (14) or colon cancer–specific mortality (15) and overall mortality (14, 15). Colon cancer survivors who engaged in higher levels of physical activity experienced a 50% to 60% improvement in long-term outcomes compared with inactive patients.

Studies have suggested that energy balance and physical activity influence certain molecular features of tumors. Obesity and/or reduced physical activity have been associated with colon cancers with p53 overexpression (16) and K-ras mutations (17, 18). Fatty acid synthase (FASN) is physiologically regulated by energy balance, and high-carbohydrate/low-fat diets up-regulate FASN (19). On the contrary, exercise and energy restriction down-regulate FASN through AMP-activated kinase (20).

Obesity, insulin, and insulin-like growth factor I influence growth and inhibit apoptosis through phosphatidylinositol 3-kinase (PIK3CA), which in turn activates Akt/protein kinase B (PKB) via phosphorylation (21). Phosphorylation of Akt (phospho-Akt) results in cell proliferation and escape from apoptosis (22). Approximately 45% of colon cancers overexpress phospho-Akt (23), which inhibits transcription and promotes degradation of the cyclin-dependent kinase inhibitor p27 (24), and in vitro studies show that insulin and insulin-like growth factor I similarly result in down-regulation of p27 (25). In animals, p27 expression increased in a dose-dependent manner in response to energy restriction and/or physical activity (26–28).

Given the association between postdiagnosis physical activity and improved survival outcomes in patients with surgically resected colon cancer (14, 15) and the influence of physical activity on molecular features of tumors, we sought to determine whether the influence of physical activity on patient survival differs depending on molecular features of the tumor. Using two large, prospective cohorts with self-reported postdiagnosis physical activity data and tumor blocks, we tested the interaction between exercise and molecular markers on colon cancer–specific and overall mortality in patients with stage I, II, and III colon cancer.

Materials and Methods

Study population

We used the databases of two large prospective cohort studies, the Nurses' Health Study (n = 121,700 women followed since 1976), and the Health Professional Follow-up Study (n = 51,500 men followed since 1986). Every 2 y, participants have been sent follow-up questionnaires to update information on potential risk factors and to identify newly diagnosed cancer and other diseases. This study was approved by the Human Subjects Committees at Brigham and Women's Hospital and the Harvard School of Public Health, both in Boston, Massachusetts.

Measurement of colon cancer and mortality

On each biennial follow-up questionnaire, participants were asked whether they had a diagnosis of colon cancer during the previous 2 y. When a participant (or next of kin for decedents) reported colon cancer, we sought permission to obtain medical records. Study physicians, while blinded to exposure data, reviewed all records related to colon cancer, and recorded American Joint Committee on Cancer tumor stage and tumor location. For nonresponders, we searched the National Death Index to discover deaths and ascertain any diagnosis of colon cancer that contributed to death or was a secondary diagnosis. The ascertainment of cases of colon cancer has been described in detail (29). The response rate for participants who had nonfatal outcomes was 96% of the possible number of person-years. We collected paraffin-embedded tissue blocks from hospitals where colon cancer patients underwent resections of primary tumors. Tissue sections from all colon cancer cases were reviewed by a pathologist (S.O.). Tumor grade was categorized as high (≤50% glandular area) or low (>50% glandular area). Based on availability of tissue samples, the current analyses have up to 487 tumor samples with physical activity assessments.

Patients were observed until death or June 2006, whichever came first. Ascertainment of deaths included reporting by the family or postal authorities. In addition, the names of persistent nonresponders were searched in the National Death Index (30). The cause of death was assigned by physicians blinded to other clinical and life-style information. In rare patients who died as a result of colon cancer not previously reported, we obtained medical records with permission from next of kin. More than 98% of deaths in the cohorts were identified by these methods (31, 32).

Exposure assessment

Since 1986, leisure-time physical activity has been assessed every 2 y in both cohorts, as previously described and validated against subject diaries (33, 34). Subjects reported duration of participation (ranging from 0-11 or more hours per week) on walking (along with usual pace), jogging, running, bicycling, swimming laps, racket sports, other aerobic exercises, lower intensity exercise (yoga, toning, stretching), or other vigorous activities.

We have previously reported that women with colon cancer who were more physically active had a statistically significant improvement in colon cancer–specific mortality compared with those engaging in minimal leisure-time physical activity (15). In that analysis, as well as the present one, to avoid bias due to declining activity, physical activity was not updated (only a single postdiagnosis measurement was used).

Each activity on the questionnaire was assigned a metabolic equivalent task (MET) score (35). One MET is the energy expenditure for sitting quietly. MET scores are defined as the ratio of the metabolic rate associated with specific activities divided by the resting metabolic rate. The values from the individual activities were summed for a total MET-hours per week score. Based on prior studies of physical activity in colon cancer survivors, patients who engaged in at least 18 MET-hours per week had significantly improved colon cancer–specific mortality (14, 15). For primary analyses, we dichotomized physical activity to <18 MET-hours per week and ≥18 MET-hours per week.

Since our prior studies have found an association between physical activity after diagnosis and survival (14, 15), the first physical activity assessment collected at least 1 y but no >4 y after diagnosis (median, 17 mo) was used to avoid assessment during the period of active treatment.

Covariates

Stage of disease, grade of tumor differentiation, year of diagnosis, and location of tumor were extracted from the medical record. The time interval between cancer diagnosis and assessment of activity was also adjusted for in these analyses. Body mass index (BMI) was also obtained from the biennial questionnaire at the time of the respective physical activity assessment.

Immunohistochemistry for FASN, p53, p21, and p27

Tissue microarrays (TMA) were constructed and immunohistochemistry for FASN, p53, p21, and p27 was done as previously described (36–39). Appropriate positive and negative controls were included in each run for each marker's immunohistochemistry. All immunohistochemically stained slides were interpreted by a pathologist (S.O.) blinded from any other laboratory data.

FASN expression was categorized as negative (no or weak expression) or positive (strong expression). For p53, we visually estimated the fraction of tumor cells with strong and unequivocal nuclear staining, by examining at least two tissue cores in TMAs, or the whole tissue section in each case for which there was not enough tissue for TMAs or results were equivocal in TMAs. p53 positivity was defined as 50% or more of tumor cells with moderate or strong staining. For p21 immunohistochemistry, normal colonic mucosa or rare mesenchymal cells served as internal positive control. We visually estimated the fraction of tumor cells expressing p21, using the whole tissue section on a single slide for every case. p21 expression was interpreted as loss in <20% of cells were positive and “expressed” if ≥20% of cells were positive. The extent of nuclear p27 expression was visually estimated using whole tissue sections, and interpreted as “loss” (no staining, only weakly staining, or <20% of tumor cells positive for moderate/strong staining) or expressed if moderate/strong positive in ≥20% of cells.

A random selection of 114 to 246 cases was reexamined for each marker by a second pathologist (p53 and FASN by K.N.; p21 and p27 by K.S.) unaware of other data, and concordance rates and κ coefficients between the two pathologists were as follows: 0.87 (κ = 0.75; n = 118) for p53, 0.93 (κ = 0.57; n = 246) for FASN, 0.83 (κ = 0.62; n = 179) for p21, and 0.94 (κ = 0.60; n = 114) for p27.

Pyrosequencing for K-ras and PIK3CA

Genomic DNA was extracted from dissected tumor tissue sections using QIAmp DNA Mini kit (Qiagen; ref. 40). Normal DNA was obtained from colonic tissue at resection margins. Whole genome amplification of genomic DNA was done by PCR using random 15-mer primers. PCR and Pyrosequencing were done as previously described (40, 41).

Statistical analysis

Cox proportional hazards models were used to calculate hazard ratios of colon cancer–specific death from colon cancer, adjusted for other risk factors for cancer survival. Death from colon cancer was the primary end point and deaths from other causes were censored. Participants were followed from the date of return of postdiagnosis physical activity assessment to either death or June 2006, whichever came first. Modeling was done by entering physical activity in the model and stratifying by the molecular marker and by entering the molecular marker and stratifying by physical activity. Tests of interactions between physical activity categories and molecular markers were assessed by entering in the model the cross product of the dichotomized physical activity variable and the dichotomized molecular marker. No formal adjustments for multiple hypothesis testing were done but considered when interpreting results. All analyses used SAS version 8.0 (SAS Institute, Inc.).

Results

Baseline characteristics

At the time of analyses of these two cohorts, 1,024 subjects had available tumor blocks. Of those, 678 were colon cancers. Eight patients were excluded due to having another cancer diagnosis within 3 years of the colon cancer, 25 patients were excluded for not having a diagnosis of colon in the time frame of 1986 to 2006 (physical activity assessments began in 1986), and 81 patients were excluded for stage IV colon cancer (eligible sample size based on blocks was 564). Of those patients, 488 had a measurement of physical activity within 4 years of diagnosis (median time to assessment, 17 months with 95% within 30 months after diagnosis) but 4 patients died within 6 months of the activity assessment and thus were excluded (consistent with our prior analyses). Thus, 484 colon cancer patients without evidence of metastatic disease at diagnosis were included in these analyses (Table 1). When considering all subjects in the cohort that meet the inclusion/exclusion criteria (colon cancer, not stage IV at diagnosis, time frame of study, having appropriate postdiagnosis physical activity assessment), no significant changes were seen in baseline characteristics with and without blocks available for analysis (data not shown). Sixty-three percent (n = 307) reported physical activity levels of <18 MET-hours per week, whereas 37% (n = 177) engaged in 18 or greater MET-hours per week. The median age at diagnosis, median BMI, year of diagnosis distribution, and median time from diagnosis to physical activity assessment were similar between the two exercise categories. Those engaging in <18 MET-hours per week were more likely to be female, whereas those with at least 18 MET-hours per week of exercise were more likely to be male. Stage distribution was fairly similar, although there was a higher percentage of stage I versus II patients in the less active cohort and higher percentage of stage II versus I patients in the more active cohort.

View this table:
  • View inline
  • View popup
Table 1.

Baseline characteristics of patients with tumor samples included in this study by level of physical activity

Impact of physical activity on outcomes by molecular markers

We have previously reported that higher levels of physical activity after colon cancer diagnosis was associated with better colon cancer–specific and overall mortality (14, 15). We did subgroup analyses by individual molecular markers comparing <18 MET-hours/week of exercise to at least 18 MET-hours/week on colon cancer–specific mortality (Table 2). A protective association for increased physical activity was detected regardless of FASN, K-ras, p53, or p21 status; no significant interactions were detected for these markers. In contrast, the effect of physical activity on patient outcome seemed to differ significantly according to p27 status (Pinteraction = 0.03). For patients with loss of p27, regular physical activity conferred no benefit, whereas among patients with tumoral expression of p27 intact, physical activity was associated with a significant reduction in colon cancer–specific mortality (hazard ratio, 0.32; 95% confidence interval, 0.12-0.85). The benefit associated with physical activity seemed to be absent among patients with PI3KCA mutations, although a test for statistical interaction was not significant.

View this table:
  • View inline
  • View popup
Table 2.

Subgroup analyses by molecular markers for colon cancer–specific mortality comparing high to low levels of physical activity

Increased levels of physical activity were associated with a statistically significant 40% improvement in overall mortality in this cohort of stage I to III colon cancer patients with tumor blocks and physical activity assessment at least 6 months after diagnosis (Table 3). These results were largely unchanged by status of FASN, K-ras, p53, p21, p27, and PIK3CA in the primary tumors.

View this table:
  • View inline
  • View popup
Table 3.

Subgroup analyses by molecular markers for overall mortality comparing high to low levels of physical activity

We tested whether any of the markers confounded the previously reported associations between physical activity and either colon cancer–specific mortality or overall mortality. Adding the status of these six markers, either individually or all in the same model, did not impact on the multivariate hazard models (data not shown).

Discussion

Prospective observational data suggest that physically active colon cancer survivors have lower rates of cancer recurrence and improved survival compared with inactive survivors (14, 15). However, as with any oncological intervention, it is likely that not all patients derive a benefit from exercise. We tested molecular pathways that have been associated with energy balance to determine if a population of colon cancer survivors particularly benefits from physical activity. Surveying a variety of molecular events, we found that the benefit associated with physical activity differed significantly according p27 expression. Patients with loss of p27 did not seem to benefit from physical activity but those with expression of p27 and were physically active (at least 18 MET-hours/week) had a 68% improvement in colon cancer–specific mortality compared with those with p27 expression but not physically active.

Personalized medicine is a growing goal in the treatment of cancer patients (42). It is clear that individual pharmacologic interventions will not impact all patients with the same cancer type. As such, there is growing interest to find markers that better differentiate patients that are likely to benefit from a treatment from patients that have little to no chance of deriving benefit. Similarly, as evidence grows that nondrug therapies can influence patients with established cancer, there is a need to better delineate subpopulations of cancers that may or may not be more likely to be impacted by an intervention. Given the consistent evidence suggesting that physical activity reduces colon cancer recurrences in early stage patients (14, 15, 43), we hypothesized that certain characteristics of a patient's tumor may interact with the biological effects of exercise. With the exception of p27, no such interaction was detected for colon cancer–specific or overall mortality. Further, although the P for interaction between p27 and physical activity was statistically significant for colon cancer–specific mortality (P = 0.03), there was no significant interaction for overall mortality (P = 0.37).

In preclinical models, higher levels of p27 expression were detected in chemically induced malignancies in animals that were energy restricted compared with those not restricted (26–28). Such an effect will arrest cell cycle progression. Thus, the interaction detected in our data is consistent with a hypothesis that energy restriction by physical activity could influence p27-expressing tumors by cell cycle arrest inhibiting growth. Excess energy balance may have a much stronger impact on tumor behavior if tumor cells can up-regulate p27 to arrest cell cycle, than if tumor cells have lost the ability to up-regulate p27, possibly through the constitutive activation of the AKT1 pathway. However, it is not clear why no such benefit was detected for overall mortality. One explanation is that those with p27-expressing tumors clearly derive a benefit from exercise related to their colon cancer but that exercise still is beneficial to all patients irregardless of p27 status and equally protective for overall mortality related to noncancer-related causes (e.g., cardiovascular disease). Another possibility is that the finding for colon cancer–specific mortality is by chance alone, a risk of multiple hypothesis testing.

The use of the Nurse's Health Study and Health Professional Follow-up Study cohorts provides multiple advantages to study molecular-environment interactions. Diet and life-style are prospectively collected and entered into a database blind to a patient's diagnosis. Data are updated every 2 years. Tumor block ascertainment has been fairly high (∼60%). Subjects are treated at hospitals throughout the United States and represent diverse treatment approaches that could be considered generalizable on a population level. However, a limitation of this study is that cancer treatment data are not available for most patients in our cohorts. Nonetheless, it is unlikely that chemotherapy use differed according to molecular characteristics of the tumor beyond typical pathologic features like stage of disease and grade of differentiation (which are adjusted for in multivariate models). In addition, beyond cause of mortality, data on cancer recurrences were not available in these cohorts. Nonetheless, given the median survival for metastatic colon cancer was approximately 10 to 12 months during much of the time period of this study (44), colon cancer–specific survival should be a reasonable surrogate for cancer-specific outcomes. Finally, these data are limited to patients that were alive to have their physical activity assessed after diagnosis (median, 17 months). As such, conclusions are limited to that population.

In conclusion, this large prospective study of colon cancer patients confirms an association between physical activity and lower colon cancer–specific and overall mortality in colon cancer survivors. However, a molecular signature influencing this association was not clearly detected. Although p27 status may be relevant, these findings require confirmation in independent populations of colon cancer patients.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank the Nurses' Health Study and Health Professionals Follow-up Study cohort participants who have generously agreed to provide us with biological specimens and information through responses to questionnaires; hospitals and pathology departments throughout the U.S. for generously providing archival tumor specimens; and Walter Willett, Susan Hankinson, and many other staff members who implemented and have maintained the cohort studies.

Footnotes

  • Grant support:US NIH grants P01 CA87969 (principal investigator: Hankinson), P01 CA55075 (principal investigator: Willett), P50 CA127003 (principal investigator: Fuchs), K07 CA097992 (principal investigator: Meyerhardt), K07 CA122826 (principal investigator: Ogino), and in part by the Bennett Family Fund for Targeted Therapies Research and the Entertainment Industry Foundation through the EIF National Colorectal Cancer Research Alliance. None of these funding agencies has not had any role in design or conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript.

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Received February 25, 2009.
    • Revision received May 21, 2009.
    • Accepted June 15, 2009.

References

  1. ↵
    1. Lee IM,
    2. Paffenbarger RS, Jr,
    3. Hsieh C
    . Physical activity and risk of developing colorectal cancer among college alumni. J Natl Cancer Inst 1991;83:1324–9.
    OpenUrlAbstract/FREE Full Text
    1. Gerhardsson M,
    2. Floderus B,
    3. Norell SE
    . Physical activity and colon cancer risk. Int J Epidemiol 1988;17:743–6.
    OpenUrlAbstract/FREE Full Text
    1. Martinez ME,
    2. Giovannucci E,
    3. Spiegelman D,
    4. Hunter DJ,
    5. Willett WC,
    6. Colditz G
    . A. Leisure-time physical activity, body size, and colon cancer in women. Nurses' Health Study Research Group. J Natl Cancer Inst 1997;89:948–55.
    OpenUrlAbstract/FREE Full Text
    1. Wu AH,
    2. Paganini-Hill A,
    3. Ross RK,
    4. Henderson BE
    . Alcohol, physical activity and other risk factors for colorectal cancer: a prospective study. Br J Cancer 1987;55:687–94.
    OpenUrlCrossRefPubMed
    1. Thun MJ,
    2. Calle EE,
    3. Namboodiri MM,
    4. et al
    . Risk factors for fatal colon cancer in a large prospective study. J Natl Cancer Inst 1992;84:1491–500.
    OpenUrlAbstract/FREE Full Text
    1. Ballard-Barbash R,
    2. Schatzkin A,
    3. Albanes D,
    4. et al
    . Physical activity and risk of large bowel cancer in the Framingham Study. Cancer Res 1990;50:3610–3.
    OpenUrlAbstract/FREE Full Text
    1. Albanes D,
    2. Blair A,
    3. Taylor PR
    . Physical activity and risk of cancer in the NHANES I population. Am J Public Health 1989;79:744–50.
    OpenUrlPubMed
    1. Severson RK,
    2. Nomura AM,
    3. Grove JS,
    4. Stemmermann GN
    . A prospective analysis of physical activity and cancer. Am J Epidemiol 1989;130:522–9.
    OpenUrlAbstract/FREE Full Text
    1. Lynge E,
    2. Thygesen L
    . Use of surveillance systems for occupational cancer: data from the Danish National system. Int J Epidemiol 1988;17:493–500.
    OpenUrlAbstract/FREE Full Text
    1. Paffenbarger RS, Jr,
    2. Hyde RT,
    3. Wing AL
    . Physical activity and incidence of cancer in diverse populations: a preliminary report. Am J Clin Nutr 1987;45:312–7.
    OpenUrlFREE Full Text
  2. ↵
    1. Giovannucci E,
    2. Ascherio A,
    3. Rimm EB,
    4. Colditz GA,
    5. Stampfer MJ,
    6. Willett WC
    . Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med 1995;122:327–34.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Samad AK,
    2. Taylor RS,
    3. Marshall T,
    4. Chapman MA
    . A meta-analysis of the association of physical activity with reduced risk of colorectal cancer. Colorectal Dis 2005;7:204–13.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Vainio H,
    2. Kaaks R,
    3. Bianchini F
    . Weight control and physical activity in cancer prevention: international evaluation of the evidence. Eur J Cancer Prev 2002;11 Suppl 2:S94–100.
    OpenUrlPubMed
  5. ↵
    1. Meyerhardt JA,
    2. Heseltine D,
    3. Niedzwiecki D,
    4. et al
    . Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol 2006;24:3535–41.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Meyerhardt JA,
    2. Giovannucci EL,
    3. Holmes MD,
    4. et al
    . Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol 2006;24:3527–34.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Zhang ZF,
    2. Zeng ZS,
    3. Sarkis AS,
    4. et al
    . Family history of cancer, body weight, and p53 nuclear overexpression in Duke's C colorectal cancer. Br J Cancer 1995;71:888–93.
    OpenUrlPubMed
  8. ↵
    1. Martinez ME,
    2. Maltzman T,
    3. Marshall JR,
    4. et al
    . Risk factors for Ki-ras protooncogene mutation in sporadic colorectal adenomas. Cancer Res 1999;59:5181–5.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Slattery ML,
    2. Anderson K,
    3. Curtin K,
    4. et al
    . Lifestyle factors and Ki-ras mutations in colon cancer tumors. Mutat Res 2001;483:73–81.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Semenkovich CF
    . Regulation of fatty acid synthase (FAS). Prog Lipid Res 1997;36:43–53.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Motoshima H,
    2. Goldstein BJ,
    3. Igata M,
    4. Araki E
    . AMPK and cell proliferation-AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 2006;574:63–71.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Imai Y,
    2. Clemmons DR
    . Roles of phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways in stimulation of vascular smooth muscle cell migration and deoxyriboncleic acid synthesis by insulin-like growth factor-I. Endocrinology 1999;140:4228–35.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Vivanco I,
    2. Sawyers CL
    . The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489–501.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Itoh N,
    2. Semba S,
    3. Ito M,
    4. Takeda H,
    5. Kawata S,
    6. Yamakawa M
    . Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer 2002;94:3127–34.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Medema RH,
    2. Kops GJ,
    3. Bos JL,
    4. Burgering BM
    . AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 2000;404:782–7.
    OpenUrlCrossRefPubMed
  16. ↵
    1. von Harsdorf R,
    2. Hauck L,
    3. Mehrhof F,
    4. Wegenka U,
    5. Cardoso MC,
    6. Dietz R
    . E2F-1 overexpression in cardiomyocytes induces downregulation of p21CIP1 and p27KIP1 and release of active cyclin-dependent kinases in the presence of insulin-like growth factor I. Circ Res 1999;85:128–36.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Zhu Z,
    2. Jiang W,
    3. Thompson HJ
    . Effect of energy restriction on the expression of cyclin D1 and p27 during premalignant and malignant stages of chemically induced mammary carcinogenesis. Mol Carcinog 1999;24:241–5.
    OpenUrlCrossRefPubMed
    1. Zhu Z,
    2. Jiang W,
    3. Thompson HJ
    . Effect of corticosterone administration on mammary gland development and p27 expression and their relationship to the effects of energy restriction on mammary carcinogenesis. Carcinogenesis 1998;19:2101–6.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Jiang W,
    2. Zhu Z,
    3. Thompson HJ
    . Effect of energy restriction on cell cycle machinery in 1-methyl-1-nitrosourea-induced mammary carcinomas in rats. Cancer Res 2003;63:1228–34.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Chute CG,
    2. Willett WC,
    3. Colditz GA,
    4. et al
    . A prospective study of body mass, height, and smoking on the risk of colorectal cancer in women. Cancer Causes Control 1991;2:117–24.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Sathiakumar N,
    2. Delzell E,
    3. Abdalla O
    . Using the National Death Index to obtain underlying cause of death codes. J Occup Environ Med 1998;40:808–13.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Stampfer MJ,
    2. Willett WC,
    3. Speizer FE,
    4. et al
    . Test of the National Death Index. Am J Epidemiol 1984;119:837–9.
    OpenUrlFREE Full Text
  22. ↵
    1. Rich-Edwards JW,
    2. Corsano KA,
    3. Stampfer MJ
    . Test of the National Death Index and Equifax Nationwide Death Search. Am J Epidemiol 1994;140:1016–9.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Wolf AM,
    2. Hunter DJ,
    3. Colditz GA,
    4. et al
    . Reproducibility and validity of a self-administered physical activity questionnaire. Int J Epidemiol 1994;23:991–9.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Chasan-Taber S,
    2. Rimm EB,
    3. Stampfer MJ,
    4. et al
    . Reproducibility and validity of a self-administered physical activity questionnaire for male health professionals. Epidemiology 1996;7:81–6.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Ainsworth BE,
    2. Haskell WL,
    3. Leon AS,
    4. et al
    . Compendium of physical activities: classification of energy costs of human physical activities. Med Sci Sports Exerc 1993;25:71–80.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Ogino S,
    2. Brahmandam M,
    3. Kawasaki T,
    4. Kirkner GJ,
    5. Loda M,
    6. Fuchs CS
    . Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Neoplasia 2006;8:458–64.
    OpenUrlCrossRefPubMed
    1. Ogino S,
    2. Kawasaki T,
    3. Kirkner GJ,
    4. et al
    . Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer. J Pathol 2006;210:147–54.
    OpenUrlCrossRefPubMed
    1. Ogino S,
    2. Kawasaki T,
    3. Kirkner GJ,
    4. Yamaji T,
    5. Loda M,
    6. Fuchs CS
    . Loss of nuclear p27 (CDKN1B/KIP1) in colorectal cancer is correlated with microsatellite instability and CIMP. Mod Pathol 2007;20:15–22.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Ogino S,
    2. Kawasaki T,
    3. Ogawa A,
    4. Kirkner GJ,
    5. Loda M,
    6. Fuchs CS
    . Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype. Hum Pathol 2007;38:842–9.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Ogino S,
    2. Kawasaki T,
    3. Brahmandam M,
    4. et al
    . Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 2005;7:413–21.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Nosho K,
    2. Kawasaki T,
    3. Ohnishi M,
    4. et al
    . PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 2008;10:534–41.
    OpenUrlPubMed
  30. ↵
    1. Gralow J,
    2. Ozols RF,
    3. Bajorin DF,
    4. et al
    . Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening—a report from the American Society of Clinical Oncology. J Clin Oncol 2008;26:313–25.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Haydon AM,
    2. Macinnis RJ,
    3. English DR,
    4. Giles GG
    . Effect of physical activity and body size on survival after diagnosis with colorectal cancer. Gut 2006;55:62–7.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Meyerhardt JA,
    2. Mayer RJ
    . Systemic therapy for colorectal cancer. N Engl J Med 2005;352:476–87.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Clinical Cancer Research: 15 (18)
September 2009
Volume 15, Issue 18
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Interaction of Molecular Markers and Physical Activity on Mortality in Patients with Colon Cancer
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
Citation Tools
Interaction of Molecular Markers and Physical Activity on Mortality in Patients with Colon Cancer
Jeffrey A. Meyerhardt, Shuji Ogino, Gregory J. Kirkner, Andrew T. Chan, Brian Wolpin, Kimmie Ng, Katsuhiko Nosho, Kaori Shima, Edward L. Giovannucci, Massimo Loda and Charles S. Fuchs
Clin Cancer Res September 15 2009 (15) (18) 5931-5936; DOI: 10.1158/1078-0432.CCR-09-0496

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Interaction of Molecular Markers and Physical Activity on Mortality in Patients with Colon Cancer
Jeffrey A. Meyerhardt, Shuji Ogino, Gregory J. Kirkner, Andrew T. Chan, Brian Wolpin, Kimmie Ng, Katsuhiko Nosho, Kaori Shima, Edward L. Giovannucci, Massimo Loda and Charles S. Fuchs
Clin Cancer Res September 15 2009 (15) (18) 5931-5936; DOI: 10.1158/1078-0432.CCR-09-0496
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Radiation and TGFβ Blockade in Metastatic Breast Cancer
  • BRAF-HSP90 inhibition in melanoma
  • AZD5363 in Solid and PIK3CA-Mutated Cancers
Show more Cancer Therapy: Clinical
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement